SkinBioTherapeutics's total assets for Q4 2024 were £12.13M, an increase of 66.18% from the previous quarter. GB:SBTX total liabilities were £2.71M for the fiscal quarter, a -3.64% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.